Previous 10 | Next 10 |
home / stock / mdclf / mdclf news
Enrolment is complete following the randomization of 151 patients across seven centers in the US The study was initiated in November 2022 and is proceeding as planned with efficacy results anticipated in Q1 2024 F14 (mdc-CWM) is a sustained-release formulation of the non-steroidal...
2023-05-12 05:18:00 ET MedinCell ( OTC:MDCLF ) prices its global offering for a final amount of €25.1M through an offering to French and international investors via a private placement and to retail investors in France. Proceeds will be used for preclinical and c...
An original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc-TJK or TEV-44749) will be communicated by MedinCell’s partner Teva Pharmaceuticals at the 2023 Schizophrenia Investigational Research Society (S...
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals 1 In a Phase 3 clinical trial, UZEDY demonstrated up to 80% reduction in risk of schizophrenia relapse versus placebo 1 UZEDY...
Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating. Rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector. ISS, one of the world’s leading ratings agenci...
The Phase 3 study conducted in the U.S. will assess the efficacy and safety of the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine for the treatment of patients with schizophrenia. MedinCell’s partner Teva, who finances and pilots the regulatory developmen...
The study conducted in 399 participants met its primary efficacy endpoint with a reduction of 72% of COVID-19 infection in the group treated with daily oral administration of ivermectin compared to the placebo group. Ivermectin administered for 28 days demonstrated acceptable safety and t...
MedinCell (Paris:MEDCL) h as received an additional US$ 4 million payment from the Bill & Melinda Gates Foundation This amount is intended to finance the next steps of MedinCell’s program mdc-WWM in readiness to initiate the first clinical trial end of 2023 It f...
MedinCell press release (OTCPK:MDCLF): FY net loss of €24.81M. Revenue of €4.09M (-50.1% Y/Y). On March 31, 2022, MedinCell had €24.6M of cash and cash equivalents and €2.6M of current and non-current non-risky financial assets (compared to €47.1M ...
MedinCell (OTCPK:MDCLF): 1H GAAP EPS of -€0.47. Revenue of €4.08M (+29.5% Y/Y) Press Release As of September 30, 2021, MedinCell had €34.4M in cash and €3.0M in non-risky financial assets, compared to €47.1M in cash and €3.9M in non-risky financi...
News, Short Squeeze, Breakout and More Instantly...
Medical Intelligence Technologies Inc Company Name:
MDCLF Stock Symbol:
OTCMKTS Market:
Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales. Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting inj...
Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission...
Guidance for 2024 UZEDY Teva’s revenue: ~ $80 million Olanzapine LAI ongoing Phase 3: 675 patients (recruitment completed), 62% of the targeted 3,600 injections performed, no PDSS (Post injection Delirium/Sedation Syndrome) observed MedinCell (Paris:MEDCL): Access...